Calprotectin in blood, cystatin C, canine CRP @ EuroMedLab
16. May 2023 |
8 min read
Gentian @ Worldlab-EuroMedLab 2023
We look forward to share insights and news about GCAL® - plasma and serum calprotectin, Cystatin C and Canine CRP at WorldLab-EuroMedLab 2023 in Rome next week.
GCAL® is increasing its presence in routine use in hospitals and labs across Europe, and new study results confirm calprotectin's advantages in patient care at the ICU and ED, in addition to positive health economic impact. The demand for the kidney marker cystatin C is seeing a significant uptake as a result of the NKF-ASN Taskforce recommendation to increase the use of cystatin C in clinical practise improving the accuracy of eGFR in patient groups that have a risk of Chronic Kidney Disease (CKD) or those that are already diagnosed with the disease.
The Gentian Cystatin C and GCAL® assays have been IVDR certified by TüV SÜD since September 2022. Gentian has now fully implemented IVDR with the final steps of updating the products' labels and documents completed March 1st 2023. Our IVDR certified products are available on a wide range of clinical chemical clinical chemistry analysers.
Calprotectin in severe events in infections
Calprotectin is a well described biomarker with several applications in bacterial infections. It can differentiate between bacterial and viral infection1-3 and distinguish sterile inflammation, such as trauma4. This allows for more accurate and effective use of antibiotics. Early and rapid kinetics of calprotectin in bacterial infections5,10, enable it to predict the need for antibiotics before onset of clinical symptoms5. This early detection can lead to significant cost savings and improved patient outcomes11. Elevated levels of calprotectin are also a valuable risk marker for severe events such as sepsis, septic shock, and mortality3,4, 6-9 and improve classical risk scoring9. Early detection and risk stratification can thereby help to identify patients at risk for deterioration and guide decisions on course of treatment or necessary transfer of patients to ICU12.
Early detection of infection in intensive care patients - health economic impact
A health economic model identified calprotectin as cost-effective biomarker for a patient cohort presented in a Swedish ICU. The model was employed to estimate the cost-effectiveness of analysis of calprotectin for early detection of bacterial infection and thus, the earlier start of antibiotic treatment compared to other diagnostic biomarkers.
Compared to the comparators, PCT, CRP and WBCs calprotectin, analysed by the GCAL® Calprotectin Immunoassay was shown to save total costs, reduce the mean duration of in-patient care, and reduce in-hospital mortality in those patients. Although this study focuses on a health economic perspective, the main rationale of analysis of calprotectin is from a clinical perspective, since early diagnosis of severe infections and sepsis reduces both delays in treatment and mortality. From this aspect, data from the health economic model support previous studies, where early detection of severe infections and sepsis has both cost-saving and life-saving impact in the ICU setting. In the sensitivity analysis, when key model inputs are varied, calprotectin remains the dominant option.
Implementing Cystatin C for better kidney health
Estimating eGFR without the inclusion of race and sex
The European Kidney Function Consortium (EKFC) followed up on the initiative from the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) addressing the race factor in estimated Glomerular Filtration Rate (eGFR) equations in a recent study with data from over 227 000 patients.
The EKFC concluded that their newly developed cystatin C based eGFR equation that does not rely on factors for race and gender can estimate the GFR without compromising on accuracy. The EKFC also documented that an eGFR based on the average of the EKFC eGFRcys and the EKF eGFRcr (where the latter has a factor for the local population and the gender) achieves a higher accuracy for eGFR.
The preferred assay by major reference laboratories
The Gentian Canine CRP Immunoassay is a turbidimetric immunoassay for quantitative determination of canine C-reactive protein (CRP) in dog plasma and serum. Utilising canine-specific antibodies the assay ensures consistent results and limited lot variation, and due to its instrument-independent design it can be applied on clinical chemistry analysers already present in the lab.
As one of Gentian’s first assays it has been continuously available and improving canine health since 2013.
Get in touch for more information
Interested in our reagents? Want to know more?Would you like to be our business partner?Meet us at WorldLab-EuroMedLab. Book a meeting by sending an email email@example.com fill out the form below:
Havelka A et al. Scientific reports. 2020;10(1):4208-.
Siljan WW et al. ERJ Open Res. 2019;5(1).
Bartáková E et al. Diagn Microbiol Infect Dis. 2019;93(3):219-26.
Larsson A et al. Scandinavian Journal of Clinical and Laboratory Investigation. 2019:1-6.
Jonsson N et al. Crit Care Resusc. 2017;19(3):205-13.
Gao S et al. Am J Emerg Med. 2015;33(9):1278-82.
Parke Å et al. Critical Care. 2020;24(1):P477.
Wirtz TH et al. Diagnostics (Basel). 2020;10(11):990.
Dubois C et al. Scientific Reports. 2019;9(1).
Fullerton J et al. Critical Care. 2020;24(1):P474.
Havelka AL, M.; Hultström, M.; Larsson, A., editor Health economic impact of use of GCAL® calprotectin immunoassay for early detection of infection in intensive care patients International Symposium on Intensive Care and Emergency Medicine (ISICEM) meeting; 2023; Brussels.